 Metodology. A total of 17 FIGO stage IIIB patients with histologically confirmed cervical carcinoma with no previous treatment will be included. Patients will be typed for acetylator status and and then receive either 182 or 83 mg of hydralazine, and magnesium valproate at 40mgKg from day -7 to the end of chemoradiation external and brachytherapy. Clinical response rate, safety and transcriptome changes will be analyzed. 